Search company, investor...

Neurogen

neurogen.com

Founded Year

1987

Stage

Acq - P2P | Acquired

About Neurogen

Neurogen is both in the discovery and development of new drug candidates and in the development and integration of new drug-discovery technology, most notably its AIDD (Accelerated Intelligent Drug Discovery) system. Neurogen's new drug programs promise improved efficacy and reduced side effects in treating psychiatric, metabolic and inflammatory disorders.

Headquarters Location

45 Northeast Industrial Road

Branford, Connecticut, 06405,

United States

203-488-8201

Missing: Neurogen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neurogen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Neurogen Patents

Neurogen has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/28/2006

12/14/2010

G protein coupled receptors, Olfactory receptors, Imidazoles, Protein domains, Protein families

Grant

Application Date

7/28/2006

Grant Date

12/14/2010

Title

Related Topics

G protein coupled receptors, Olfactory receptors, Imidazoles, Protein domains, Protein families

Status

Grant

Latest Neurogen News

SciFluor Life Sciences Raises $30 Million and Names William Koster PhD Former CEO of Neurogen Corp. as Chairman

Apr 22, 2015

PRA Health raises 6M in IPO The company also named William Koster, PhD, a seasoned executive in drug discovery research and early clinical development, as Chairman of the Board. Koster previously served as President and Chief Executive Officer of Neurogen Corp., a NASDAQ-listed biotechnology company engaged in neuroscience R&D. He also spent 30 years with Bristol-Myers Squibb Co. in various roles that included Senior Vice President overseeing worldwide drug discovery research and early clinical development through Phase 2a. SciFluor is focusing its efforts on the strategic use of fluorine to create new drugs with improved potency, selectivity, dosing, and metabolic stability across multiple disease states, including retinal disease, CNS disorders, pain, pulmonary and inflammatory disease. The company recently announced the issuance of two U.S. patents for its potentially breakthrough lead compounds to treat retinal diseases and epilepsy. Treatments for retinal diseases, such as Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), represent a more than $6 billion market opportunity, and those for epilepsy and related disorders are estimated at more than $7 billion. “This successful funding round will enable SciFluor to accelerate the development and commercialization of fluorine-enhanced drug therapies,” said Omar Amirana, MD, SciFluor’s Chief Executive Officer and Senior Vice President at Allied Minds. “We are delighted with the support of our investors and warmly welcome Bill to the Board. His guidance will be tremendously valuable.” Significant participants in the funding round are Invesco Asset Management (Invesco), Woodford Investment Management (Woodford) and Allied Minds, SciFluor’s parent company. SciFluor’s two recent patents included one for SF0166, a small molecule integrin antagonist designed to topically treat retinal disease, including Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), via eye drop administration to the surface of the eye. SciFluor also received a patent for SF0034, a potent and selective neuronal potassium channel activator intended to be a significantly improved drug relative to the first-in-class KCNQ2/3 activator drug, ezogabine (POTIGA®). SF0034 is targeted for development in partial-onset epilepsy and potentially for a recently identified orphan disease, a rare disorder known as KCNQ2 pediatric encephalopathy. “SciFluor is successfully making the transition to a clinical development company. The opportunity to place these innovative discoveries into protocols for clinical testing and development is incredibly exciting, and I’m pleased to be a part of the next stage of this company’s commercial development,” said Koster. More information about SciFluor can be found at www.scifluor.com . SciFluor will be presenting at a Capital Markets Day event to be hosted by Allied Minds on 28 April at Etc. Venues St. Paul’s, 200 Aldersgate St., London. SciFluor will be presenting alongside Allied Minds’ subsidiary businesses Spin Transfer Technologies, Federated Wireless, Allied-Bristol Life Sciences and OptioLabs. About SciFluor Life Sciences SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a broad portfolio of differentiated best-in-class therapeutics to treat various diseases. The company creates patentable new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, dosing, and patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a diverse range of therapeutic categories and disease areas, including retinal disease, CNS disorders, pain, pulmonary and inflammatory disease. More information about SciFluor can be found at www.scifluor.com . About Allied Minds Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com . Allied Minds Forward-Looking Statement This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company’s regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. ArcPoint Strategic Communications

Neurogen Frequently Asked Questions (FAQ)

  • When was Neurogen founded?

    Neurogen was founded in 1987.

  • Where is Neurogen's headquarters?

    Neurogen's headquarters is located at 45 Northeast Industrial Road, Branford.

  • What is Neurogen's latest funding round?

    Neurogen's latest funding round is Acq - P2P.

  • Who are the investors of Neurogen?

    Investors of Neurogen include Ligand Pharmaceuticals, Clarion Capital Partners, Baker Brothers Investments, Warburg Pincus, Perceptive Advisors and 19 more.

  • Who are Neurogen's competitors?

    Competitors of Neurogen include ChemoCentryx, Oligomerix, Array Biopharma, BaroFold, Threshold Pharmaceuticals and 12 more.

Compare Neurogen to Competitors

D
Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

E
Escientia

is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.

Cerecin Logo
Cerecin

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.

B
Bionovo

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.

M
Mimetica

Mimetica is a Brisbane-based biotechnology company which has developed a class of small molecule scaffolds that mimic reverse-turn motifs of peptides. These scaffolds have been used to create small molecule mimics of several important peptides and proteins known to be involved in the pathogenesis of disease. Mimetica is currently focusing its initial drug development activities on dermatological applications.

Oligomerix Logo
Oligomerix

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.